Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Hojas, S"" wg kryterium: Autor


Tytuł :
Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer.
Autorzy :
Perakis SO; Institute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria.
Weber S; Institute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria.
Zhou Q; Institute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria.
Graf R; Institute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria.
Hojas S; Department of Internal Medicine, LKH Fuerstenfeld, Fuerstenfeld, Austria.
Riedl JM; Department of Internal Medicine, Division of Oncology, Medical University of Graz, Graz, Austria.
Gerger A; Department of Internal Medicine, Division of Oncology, Medical University of Graz, Graz, Austria.
Dandachi N; Department of Internal Medicine, Division of Oncology, Medical University of Graz, Graz, Austria.
Balic M; Department of Internal Medicine, Division of Oncology, Medical University of Graz, Graz, Austria.
Hoefler G; Institute of Pathology, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria.
Schuuring E; Department of Pathology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands.
Groen HJM; Department of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands.
Geigl JB; Institute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria.
Heitzer E; Institute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria; Christian Doppler Laboratory for Liquid Biopsies for Early Detection of Cancer, Graz, Austria; BioTechMed-Graz, Graz, Austria. Electronic address: .
Speicher MR; Institute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria; BioTechMed-Graz, Graz, Austria. Electronic address: .
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2020 Sep; Vol. 5 (5), pp. e000872.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Czasopismo naukowe
Tytuł :
Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.
Autorzy :
Pleyer L; 3rd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory for Immunological and Molecular Cancer Research, Oncologic Center, Paracelsus Medical University, Salzburg 5020, Austria. .; Cancer Cluster, Salzburg 5020, Austria. .
Döhner H; Department of Medicine and Internal Medicine III, Universitätsklinikum Ulm, Ulm D-89081, Germany. .
Dombret H; Institut Universitaire d'Hématologie, Hôpital Saint Louis, University Paris Diderot, Paris 75010, France. .
Seymour JF; Peter MacCallum Cancer Centre, East Melbourne, Australia, and University of Melbourne, Parkville 3000, Australia. .
Schuh AC; Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada. .
Beach CL; Celgene Corporation, Summit, NJ 07901, USA. .
Swern AS; Celgene Corporation, Summit, NJ 07901, USA. .
Burgstaller S; Department of Internal Medicine IV, Klinikum WelsGrieskirchen, Wels 4600, Austria. .
Stauder R; Department of Internal Medicine V, Innsbruck Medical University, Innsbruck 6020, Austria. .
Girschikofsky M; Department of Hematology and Oncology, Elisabethinen Hospital, Linz 4020, Austria. .
Sill H; Department of Hematology, Medical University of Graz, Graz 8036, Austria. .
Schlick K; 3rd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory for Immunological and Molecular Cancer Research, Oncologic Center, Paracelsus Medical University, Salzburg 5020, Austria. .
Thaler J; Department of Internal Medicine IV, Klinikum WelsGrieskirchen, Wels 4600, Austria. .
Halter B; Department of Internal Medicine V, Innsbruck Medical University, Innsbruck 6020, Austria. .
Machherndl Spandl S; Department of Hematology and Oncology, Elisabethinen Hospital, Linz 4020, Austria. .
Zebisch A; Department of Hematology, Medical University of Graz, Graz 8036, Austria. .
Pichler A; Department for Hematology and Oncology, LKH Leoben, Leoben 8700, Austria. .
Pfeilstöcker M; 3rd Medical Department for Hematology and Oncology, Hanusch Hospital, Vienna 1140, Austria. .
Autzinger EM; First Medical Department, Center for Oncology, Hematology and Palliative Care, Wilhelminenspital, Vienna 1160, Austria. .
Lang A; Department of Internal Medicine, Landeskrankenhaus Feldkirch (LKH) Feldkirch, Feldkirch 6800, Austria. .
Geissler K; 5th Medical Department, Hospital Hietzing, Vienna 1130, Austria. .
Voskova D; Department of Internal Medicine III, General Hospital, Linz 4020, Austria. .
Sperr WR; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna 1090, Austria. .
Hojas S; Department of Internal Medicine, LKH Fürstenfeld, Fürstenfeld 8280, Austria. sabineelisabeth.hojas@kages.at.
Rogulj IM; Department of Hematology, Clinical Hospital Merkur, Zagreb 10000, Croatia. .
Andel J; Department of Internal Medicine II, LKH Steyr, Steyr 4400, Austria. .
Greil R; 3rd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory for Immunological and Molecular Cancer Research, Oncologic Center, Paracelsus Medical University, Salzburg 5020, Austria. .; Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials, Salzburg 5020, Austria. .; Cancer Cluster, Salzburg 5020, Austria. .
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2017 Feb 15; Vol. 18 (2). Date of Electronic Publication: 2017 Feb 15.
Typ publikacji :
Journal Article
MeSH Terms :
Antimetabolites, Antineoplastic/*therapeutic use
Azacitidine/*therapeutic use
Leukemia, Myeloid, Acute/*drug therapy
Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Austria ; Azacitidine/administration & dosage ; Bone Marrow/pathology ; Clinical Trials, Phase III as Topic ; Female ; Humans ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/mortality ; Male ; Middle Aged ; Proportional Hazards Models ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.
Autorzy :
Pleyer L; 3rd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory for Immunological and Molecular Cancer Research, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria. .; Center for Clinical Cancer and Immunology Trials at Salzburg Cancer Research Institute, Salzburg, Austria. .; Cancer Cluster Salzburg, Salzburg, Austria. .
Burgstaller S; Department of Internal Medicine IV, Klinikum Wels-Grieskirchen, Wels, Austria.
Stauder R; Department of Internal Medicine V, Innsbruck Medical University, Innsbruck, Austria.
Girschikofsky M; Department of Hematology and Oncology, Elisabethinen Hospital, Linz, Austria.
Sill H; Department of Hematology, Medical University of Graz, Graz, Austria.
Schlick K; 3rd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory for Immunological and Molecular Cancer Research, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria.; Center for Clinical Cancer and Immunology Trials at Salzburg Cancer Research Institute, Salzburg, Austria.; Cancer Cluster Salzburg, Salzburg, Austria.
Thaler J; Department of Internal Medicine IV, Klinikum Wels-Grieskirchen, Wels, Austria.
Halter B; Department of Internal Medicine V, Innsbruck Medical University, Innsbruck, Austria.
Machherndl-Spandl S; Department of Hematology and Oncology, Elisabethinen Hospital, Linz, Austria.
Zebisch A; Department of Hematology, Medical University of Graz, Graz, Austria.
Pichler A; Department for Hematology and Oncology, LKH Leoben, Leoben, Austria.
Pfeilstöcker M; 3rd Medical Department for Hematology and Oncology, Hanusch Hospital, Vienna, Austria.
Autzinger EM; First Medical Department, Center for Oncology, Hematology and Palliative Care, Wilhelminenspital, Vienna, Austria.
Lang A; Department of Internal Medicine, LKH Feldkirch, Feldkirch, Austria.
Geissler K; 5th Medical Department, Hospital Hietzing, Vienna, Austria.
Voskova D; Department of Internal Medicine III, General Hospital, Linz, Austria.
Geissler D; 1st Medical department, Klinikum Klagenfurt, Klagenfurt, Austria.
Sperr WR; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
Hojas S; Department of Internal Medicine, LKH Fürstenfeld, Fürstenfeld, Austria.
Rogulj IM; Department of Hematology, Clinical Hospital Merkur, Zagreb, Croatia.
Andel J; Department of Internal Medicine II, LKH Steyr, Steyr, Austria.
Greil R; 3rd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory for Immunological and Molecular Cancer Research, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria.; Center for Clinical Cancer and Immunology Trials at Salzburg Cancer Research Institute, Salzburg, Austria.; Cancer Cluster Salzburg, Salzburg, Austria.
Pokaż więcej
Źródło :
Journal of hematology & oncology [J Hematol Oncol] 2016 Apr 16; Vol. 9, pp. 39. Date of Electronic Publication: 2016 Apr 16.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Azacitidine/*therapeutic use
Leukemia, Myeloid/*drug therapy
Myelodysplastic Syndromes/*drug therapy
Registries/*statistics & numerical data
Acute Disease ; Adult ; Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic/therapeutic use ; Austria ; Female ; France ; Humans ; Kaplan-Meier Estimate ; Leukemia, Myeloid/classification ; Leukemia, Myeloid/diagnosis ; Male ; Middle Aged ; Myelodysplastic Syndromes/classification ; Myelodysplastic Syndromes/diagnosis ; Outcome Assessment, Health Care/methods ; Outcome Assessment, Health Care/statistics & numerical data ; Prognosis ; Proportional Hazards Models ; United Kingdom ; United States ; World Health Organization
Czasopismo naukowe
Tytuł :
Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Autorzy :
Vytrva N; From the Institute of Pathology (Drs Vytrva, Stacher, Regitnig, Hoefler, and Beham-Schmid) and the Division of Hematology, Department of Medicine (Dr Zinke-Cerwenka), Medical University of Graz, Graz, Austria; the Division of Hematology, Department of Medicine, General Hospital Fürstenfeld, Fürstenfeld, Austria (Dr Hojas); the Division of Hematology, Department of Medicine, General Hospital Leoben, Leoben, Austria (Dr Hubmann); and the Department of Pathology, Radiumhemmet (Dr Porwit), and the Division of Hematology, Department of Medicine (Dr Bjorkholm), Karolinska University Hospital, Stockholm, Sweden. Dr Vytrva is now with the Department of Clinical Pathology, Ryhov Hospital, Jönköping, Sweden. Dr Porwit is now with the Department of Laboratory Hematology, General Hospital of Toronto, Toronto, Ontario, Canada. Drs Vytrva and Stacher contributed equally to the study.
Stacher E
Regitnig P
Zinke-Cerwenka W
Hojas S
Hubmann E
Porwit A
Bjorkholm M
Hoefler G
Beham-Schmid C
Pokaż więcej
Źródło :
Archives of pathology & laboratory medicine [Arch Pathol Lab Med] 2014 Sep; Vol. 138 (9), pp. 1203-9.
Typ publikacji :
Case Reports; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Janus Kinase 2/*genetics
Megakaryocytes/*pathology
Mutation/*genetics
Polycythemia Vera/*pathology
Primary Myelofibrosis/*pathology
Thrombocythemia, Essential/*pathology
Adult ; Aged ; Aged, 80 and over ; Biopsy ; Bone Marrow/pathology ; Female ; Hemoglobins/metabolism ; Humans ; Leukocyte Count ; Male ; Middle Aged ; Multivariate Analysis ; Platelet Count ; Polycythemia Vera/genetics ; Primary Myelofibrosis/genetics ; Thrombocythemia, Essential/genetics
Czasopismo naukowe
Tytuł :
Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis.
Autorzy :
Burgstaller S; Innere Medizin IV, Klinikum Wels-Grieskirchen, Grieskirchnerstraße 42, 4600 Wels, Austria. />Fridrik M
Hojas S
Kühr T
Ludwig H
Mayrbäurl B
Pöhnl R
Pötscher M
Schlögl E
Zauner D
Thaler J
Gisslinger H
Pokaż więcej
Źródło :
Wiener klinische Wochenschrift [Wien Klin Wochenschr] 2013 Apr; Vol. 125 (7-8), pp. 196-9. Date of Electronic Publication: 2013 Mar 28.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Anemia/*chemically induced
Leukopenia/*chemically induced
Primary Myelofibrosis/*complications
Primary Myelofibrosis/*drug therapy
Thalidomide/*analogs & derivatives
Thrombocytopenia/*chemically induced
Aged ; Aged, 80 and over ; Austria ; Dose-Response Relationship, Drug ; Female ; Humans ; Immunologic Factors ; Lenalidomide ; Male ; Middle Aged ; Primary Myelofibrosis/diagnosis ; Thalidomide/administration & dosage ; Thalidomide/adverse effects ; Thrombocytopenia/diagnosis ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies